<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="172495">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00850642</url>
  </required_header>
  <id_info>
    <org_study_id>112046</org_study_id>
    <nct_id>NCT00850642</nct_id>
  </id_info>
  <brief_title>GSK2190915 Moderate to Severe Asthma Study</brief_title>
  <official_title>The Efficacy of Orally Administered GSK2190915 as an add-on to Current Therapy in Subjects With Moderate to Severe Asthma Who Have Elevated Sputum Neutrophils</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomised, double-blind, placebo-controlled, parallel group study to evaluate the effect
      of treatment with GSK2190915, a FLAP inhibitor, as add-on to current inhaled corticosteroid
      therapy in patients with moderate to severe asthma with elevated sputum neutrophils.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the effect of treatment with repeat oral doses of GSK2190915 on the number of neutrophils in induced sputum in moderate to severe asthmatic subjects compared with placebo.</measure>
    <time_frame>The life of the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of treatment with repeat oral doses of GSK2190915 on lung function as measured by FEV1 in subjects with moderate to severe asthma compared with placebo.</measure>
    <time_frame>The life of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability of repeat oral doses of GSK2190915 in moderate to severe asthmatic subjects compared with placebo.</measure>
    <time_frame>The life of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the systemic exposure of GSK2190915 after 12 days repeated doses in moderate to severe asthmatic subjects.</measure>
    <time_frame>The life of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of treatment with repeat oral doses of GSK2190915 on LTE4 in urine and LTB4 in blood and sputum supernatant in moderate to severe asthmatic subjects compare to placebo.</measure>
    <time_frame>The life of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of treatment with repeat oral doses of GSK2190915 on IL-17 in blood in moderate to severe asthmatic subjects compare to placebo.</measure>
    <time_frame>The life of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of treatment with repeat oral doses of GSK2190915 in sputum supernatant including changes in neutrophil elastase, myeloperoxidase and IL-8 in moderate to severe asthmatic subjects compare to placebo.</measure>
    <time_frame>The life of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate effect of treatment with repeat oral doses of GSK2190915 on changes in symptoms in moderate to severe asthmatic subjects compare to placebo.</measure>
    <time_frame>The life of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>12 day repeat dosing with placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2190915 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 day repeat dosing treatment phase with 100mg GSK2190915.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2190195 100mg</intervention_name>
    <description>GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor.</description>
    <arm_group_label>GSK2190915 100mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo :
2% (w/w) Ethanol, sucralose (5 mg/100 mL of oral solution) to 100 % (w/w) aqueous sodium carbonate buffer (0.010 M, pH 9-10)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        A subject will be eligible for inclusion in this study only if all of the following
        criteria apply:

          -  Males and females aged 18 to 65 years inclusive.

          -  Body mass index within the range 18.5-37.0 kilograms/metre2 (kg/m2).

          -  An established clinical history of Asthma in accordance with the definition by the
             GINA Guidelines [GINA, 2006]. Subjects should have at screening or within the last
             year documented reversibility (&gt;12 %) to short acting bronchodilator, or positive
             methacholine challenge, or positive histamine challenge (PC20 &lt;8mg/ml).

          -  A female subject is eligible to participate if she is of: non-childbearing potential
             defined as pre-menopausal females with documented (medical report verification)
             hysterectomy or double oophrectomy or postmenopausal defined as 12 months of
             spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels &gt;
             40 mIU/mL and estradiol &lt; 40 pg/ml (&lt;140 pmol/L) or 6 weeks postsurgical bilateral
             oophorectomy with or without hysterectomy; childbearing potential and agrees to use
             one of the contracception methods listed in Section 8.1 for an appropriate period of
             time prior to the start of dosing and until 3 months after last dose.

          -  Male subjects must agree to use one of the contraception methods listed in Section
             8.1. This criterion must be followed from the time of the first dose of study
             medication until 3 months after the last dose.

          -  Subject with moderate to severe asthma with forced expiratory volume in one second
             (FEV1) ≥ 50% of predicted.

          -  Subject who are on regular inhaled corticosteroids without or in combination with a
             regular long acting Beta 2 Agonist. The dose should be stable for at least 4 weeks
             before screening.

          -  Subjects who are taking a minimum of FP 250mg BID or equivalent.

          -  Persistent sputum neutrophilia defined by sputum neutrophils ≥ 65% with TTC &lt; 15
             million cells/g with no evidence of eosinophilia (sputum eosinophils &lt; 2%).
             Persistent is defined as the criteria being met at screening (or within the 6 months
             preceding screening) and on visit 1.

          -  Signed and dated written informed consent is obtained from the subject

          -  The subject is able to understand and comply with the protocol requirements,
             instructions and protocol-stated restrictions.

        Exclusion Criteria:

        A subject will not be eligible for inclusion in this study if any of the following
        criteria apply:

          -  Past or present disease, which as judged by the investigator or medical monitor, may
             affect the outcome of this study. These diseases include, but are not limited to,
             cardiovascular disease, malignancy, gastrointestinal disease, hepatic disease, renal
             disease, haematological disease, neurological disease, endocrine disease or pulmonary
             disease (excluding asthma but including but not confined to chronic bronchitis,
             emphysema, bronchiectasis, eosinophilic bronchitis or pulmonary fibrosis).

          -  Clinically significant abnormalities in safety laboratory analysis at screening.

          -  Subject has uncontrolled hypertension or is hypertensive at screening. Hypertension
             at screening is defined as persistent systolic BP &gt;150 mmHg or diastolic BP &gt; 90mmHg.

          -  History of asthma exacerbations or acute intercurrent respiratory illness (viral
             respiratory syndrome, bronchitis, pneumonia) for a four week period before the
             screening visit

          -  History of life-threatening asthma, defined as an asthma episode that required
             intubations and/or was associated with hypercapnoea, respiratory arrest and/or
             hypoxic seizures.

          -  Subject is unable to abstain from taking prescription or non-prescription drugs
             (including vitamins and dietary or herbal supplements) including non-steroidal
             anti-inflammatory drugs (NSAIDs), anti-depressant drugs, anti-histamines and
             anti-asthma, anti-rhinitis or hay fever medication, with the exception of ICS, LABA
             and short action beta agonists, from 14 days before screening until the follow-up
             visit unless in the opinion of the Investigator and sponsor the medication will not
             interfere with the study

          -  Administration of oral or injectable steroids within 6 weeks of screening.

          -  The subject has participated in a study with a new molecular entity during the
             previous 3 months or has participated in 4 or more clinical studies in the previous
             12 months prior to the first dosing day.

          -  Administration of anti -leukotrienne therapies for 14 days before screening and
             during the study.

          -  Administration of any vaccinations within 1 month of screening or during the study.

          -  Administration of biological therapies within 3 months of the screening visit or
             during the study

          -  Subject is undergoing allergen desensitisation therapy.

          -  Administration of OATP1B1 substrates from 2 weeks before dosing, and until all
             follow-up assessments are completed.

          -  There is a risk of non-compliance with study procedures.

          -  History of blood donation (500 mL) within 3 months of starting the clinical study.

          -  The subject regularly drinks more than 28 units of alcohol in a week if male, or 21
             units per week if female. One unit of alcohol is defined as a medium (125 ml) glass
             of wine, half a pint (250 ml) of beer or one measure (25 ml) of spirits.

          -  The subject has a screening QTc value of &gt;450msec, PR interval outside the range 120
             to 220msec or an ECG that is not suitable for QT measurements (e.g. poorly defined
             termination of the T-wave).

          -  The subject has tested positive for hepatitis C antibody or hepatitis B surface
             antigen.

          -  The subject has tested positive for HIV antibodies.

          -  The subject has a positive pre-study urine drug or urine or breath alcohol screen. A
             minimum list of drugs that will be screened for include Amphetamines, Barbituates,
             Cocaine, Opiates, Cannabinoids and Benzodiazepines.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Glasgow</city>
        <state>Lanarkshire</state>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leicester</city>
        <state>Leicestershire</state>
        <zip>LE3 9QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 30, 2016</lastchanged_date>
  <firstreceived_date>February 24, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sputum cell counts</keyword>
  <keyword>Neutrophils</keyword>
  <keyword>Severe Asthma</keyword>
  <keyword>ICS</keyword>
  <keyword>Inhaled corticosteroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>112046</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112046</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112046</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112046</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112046</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112046</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112046</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
